ReviewFrontiers in oncology2026

Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.

Anton Yu Alasheev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.